Asia Pacific Starch Softgel Capsules Market Size, Share, and Analysis by 2027

The Asia Pacific starch softgel capsule market is expected to reach US$ 122.54 million in 2027 from US$ 82.55 million in 2019. The market is estimated to grow with a CAGR of 5.2% from 2020-2027.

Factors such advantages of softgel capsules and rise in preference for vegetarian capsules Asian countries is expected to boost the market growth over the years. Moreover, developing healthcare industry in Asia Pacific region is likely to create growth opportunities for the market to grow.

The Softgel capsules are widely used in pharmaceutical industry owing to the advantages offered by the Softgel capsules over the other drug delivery forms. It offers improved patient compliance and is able to encapsulate not only solid formulations (granules, powders) but also liquid formulations (aqueous- or lipid-based) as well. Softgel capsules offer improved bioavailability as the drug is presented in solubilized form. They have flexible shapes and thus makes it easy to swallow.  Vegetarian and vegan encapsulation made from modified forms of starch and cellulose ensures that people with dietary restrictions have options to choose their supplement, vitamin and mineral choices. Softgel capsules mask odour and taste of unpleasant drug and thus can be easily swallowed. These require less adjunct as compared to tablets. The shell of the softgel capsule is inert and is easily quickly digested. They are economical, easy to handle and carry. The shells can be opacified or colored in order to protect it from light.

The advantages of Softgel capsule is likely to drive the market growth during the forecast period.

Furthermore, the novel coronavirus has been wrecking global havoc over the recent past, including Asia-Pacific. Countries in Asia-Pacific are expecting to witness huge challenge due to growing COVID-19. Considering the economic operations and geographic condition, the outbreak of disease has affected on medical tourism, manufacturing of drugs, supply chains, distributors and other problems posed by shortage of healthcare infrastructure in Asia-Pacific low-income countries. After the first case in December in Wuhan, China, the coronavirus has spread to at least 180 countries and regions. To prevent the spread of disease, restrictive measures have been taken in countries such as India, South Korea, Singapore, Malaysia, and by the Philippines. According to WHO, due to the rapidly changing risk of COVID-19 affected countries and constantly controlling outbreak trends, any additional health measures are likely to significantly interfere with international travel and trade.

Rest of Asia Pacific Starch Softgel Capsules Market Revenue and Forecast to 2027 (US$ Mn)

 

Asia Pacific Starch Softgel Capsule – Market Segmentation

By Application

• Pharmaceutical
• Health Supplements
• Others

By Distribution Channel

• Supermarket and Hypermarket
• Pharmacy and Drugstore
• Online Provider

By Country

• China
• India
• Japan
• South Korea
• Australia

Company Profiles

• Hunan Er-Kang Pharmaceutical Co. Ltd
• Softcaps
• Fuji Capsule Co. Ltd.
• Aenova Holding GmbH
• Sirio Pharma Co. Ltd.

Asia Pacific Starch Softgel Capsules Report Scope